Literature DB >> 19428846

Secreted proteins of Neisseria meningitidis protect mice against infection.

Yanwen Li1, Karl G Wooldridge, Muhammad A Javed, Christoph M Tang, Dlawer A A Ala'aldeen.   

Abstract

We addressed the hypothesis that meningococcal secreted proteins (MSPs) can elicit protective immunity against meningococcal disease. Endotoxin-depleted MSP preparations were used to immunise a group of 15 six-week-old BALB/c mice (25microg MSPs/dose mixed with Freund's complete adjuvant) on days 0, 14 and 21. Mice were challenged 2 weeks later with 10(7) colony forming units of live Neisseria meningitidis strain MC58 (serogroup B, ET-5). Negative and positive control groups of 15 mice each were injected with adjuvant only, or a live attenuated strain of MC58, respectively. Seven out of 15 mice (47%) from the negative control group died after 72h of challenge, whereas none of test or positive control group died. Protection afforded by the anti-MSP immune response can be at least partly attributed to complement-mediated bacterial lysis, detectable in vitro using the serum of immunised mice. Murine anti-MC58 MSP sera were bactericidal against homologous and five unrelated ET-5 serogroup B strains. However, failed to kill strains from other hypervirulent clonal lineages belonging to the same or different serogroups, despite the presence of cross-reactive antibodies detectable by immunoblotting. Similar sera raised against MSPs from an isolate belonging to the ET-37 electropherotype lineage were bactericidal against all tested isolates of this lineage and, in addition, against some but not all isolates belonging to the ET-5 lineage. FACS analysis of intact bacteria treated with anti-MSPs confirmed surface-binding of antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428846     DOI: 10.1016/j.vaccine.2009.02.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis.

Authors:  Kay O Johswich; Jianwei Zhou; Dennis K S Law; Frank St Michael; Shannon E McCaw; Frances B Jamieson; Andrew D Cox; Raymond S W Tsang; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2012-04-16       Impact factor: 3.441

2.  Galectin-3 binds Neisseria meningitidis and increases interaction with phagocytic cells.

Authors:  Paola Quattroni; Yanwen Li; Davide Lucchesi; Sebastian Lucas; Derek W Hood; Martin Herrmann; Hans-Joachim Gabius; Christoph M Tang; Rachel M Exley
Journal:  Cell Microbiol       Date:  2012-08-12       Impact factor: 3.715

Review 3.  Vaccine development against Neisseria meningitidis.

Authors:  Ulrich Vogel; Heike Claus
Journal:  Microb Biotechnol       Date:  2011-01       Impact factor: 5.813

4.  Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice.

Authors:  YongLi Hou; Ting Yan; Hui Cao; Peng Liu; Kang Zheng; Zhenyu Li; Qing Deng; SiHai Hu
Journal:  Int J Nanomedicine       Date:  2019-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.